Literature DB >> 7534068

Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E.

E M Castano1, F Prelli, T Wisniewski, A Golabek, R A Kumar, C Soto, B Frangione.   

Abstract

A central event in Alzheimer's disease is the conformational change from normally circulating soluble amyloid beta peptides (A beta) and tau proteins into amyloid fibrils, in the form of senile plaques and neurofibrillary tangles respectively. The apolipoprotein E (apoE) gene locus has recently been associated with late-onset Alzheimer's disease. It is not know whether apoE plays a direct role in the pathogenesis of the disease. In the present work we have investigated whether apoE can affect the known spontaneous in vitro formation of amyloid-like fibrils by synthetic A beta analogues using a thioflavine-T assay for fibril formation, electron microscopy and Congo Red staining. Our results show that, under the conditions used, apoE directly promotes amyloid fibril formation, increasing both the rate of fibrillogenesis and the total amount of amyloid formed. ApoE accelerated fibril formation of both wild-type A beta-(1-40) and A beta-(1-40A), an analogue created by the replacement of valine with alanine at residue 18, which alone produces few amyloid-like fibrils. However, apoE produced only a minimal effect on A beta-(1-40Q), found in the Dutch variant of Alzheimer's disease. When recombinant apoE isoforms were used, apoE4 was more efficient than apoE3 at enhancing amyloid formation. These in vitro observations support the hypothesis that apoE acts as a pathological chaperone, promoting the beta-pleated-sheet conformation of soluble A beta into amyloid fibres, and provide a possible explanation for the association of the apoE4 genetic isoform with Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7534068      PMCID: PMC1136559          DOI: 10.1042/bj3060599

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  43 in total

1.  Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.

Authors:  I Grundke-Iqbal; K Iqbal; M Quinlan; Y C Tung; M S Zaidi; H M Wisniewski
Journal:  J Biol Chem       Date:  1986-05-05       Impact factor: 5.157

2.  Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease.

Authors:  D J Selkoe; C R Abraham; M B Podlisny; L K Duffy
Journal:  J Neurochem       Date:  1986-06       Impact factor: 5.372

3.  Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments.

Authors:  J Ma; A Yee; H B Brewer; S Das; H Potter
Journal:  Nature       Date:  1994-11-03       Impact factor: 49.962

4.  Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein.

Authors:  G G Glenner; C W Wong
Journal:  Biochem Biophys Res Commun       Date:  1984-08-16       Impact factor: 3.575

5.  The apolipoprotein E epsilon 4 allele does not influence the clinical expression of the amyloid precursor protein gene codon 693 or 692 mutations.

Authors:  J Haan; C Van Broeckhoven; C M van Duijn; E Voorhoeve; F van Harskamp; J C van Swieten; M L Maat-Schieman; R A Roos; E Bakker
Journal:  Ann Neurol       Date:  1994-09       Impact factor: 10.422

6.  In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer's disease beta-protein.

Authors:  E M Castaño; J Ghiso; F Prelli; P D Gorevic; A Migheli; B Frangione
Journal:  Biochem Biophys Res Commun       Date:  1986-12-15       Impact factor: 3.575

7.  Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related.

Authors:  C W Wong; V Quaranta; G G Glenner
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

8.  Amyloid plaque core protein in Alzheimer disease and Down syndrome.

Authors:  C L Masters; G Simms; N A Weinman; G Multhaup; B L McDonald; K Beyreuther
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

9.  Degradation and deposition of amyloid AA fibrils are tissue specific.

Authors:  F Prelli; M Pras; B Frangione
Journal:  Biochemistry       Date:  1987-12-15       Impact factor: 3.162

Review 10.  Alzheimer's disease and soluble A beta.

Authors:  T Wisniewski; J Ghiso; B Frangione
Journal:  Neurobiol Aging       Date:  1994 Mar-Apr       Impact factor: 4.673

View more
  67 in total

Review 1.  Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.

Authors:  M Flint Beal
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

2.  ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.

Authors:  Anne M Fagan; Erin Christopher; Jennie W Taylor; Maia Parsadanian; Michael Spinner; Melanie Watson; John D Fryer; Suzanne Wahrle; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

3.  The modulating effect of mechanical changes in lipid bilayers caused by apoE-containing lipoproteins on Aβ induced membrane disruption.

Authors:  Justin Legleiter; John D Fryer; David M Holtzman; Andtomasz Kowalewski
Journal:  ACS Chem Neurosci       Date:  2011-10-19       Impact factor: 4.418

Review 4.  Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease.

Authors:  Evan Dorey; Nina Chang; Qing Yan Liu; Ze Yang; Wandong Zhang
Journal:  Neurosci Bull       Date:  2014-03-20       Impact factor: 5.203

5.  Tg-SwDI transgenic mice exhibit novel alterations in AbetaPP processing, Abeta degradation, and resilient amyloid angiopathy.

Authors:  Gregory D Van Vickle; Chera L Esh; Ian D Daugs; Tyler A Kokjohn; Walter M Kalback; R Lyle Patton; Dean C Luehrs; Douglas G Walker; Lih-Fen Lue; Thomas G Beach; Judianne Davis; William E Van Nostrand; Eduardo M Castaño; Alex E Roher
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

6.  Signal sequences for targeting of gene therapy products to subcellular compartments: the role of CRM1 in nucleocytoplasmic shuttling of the protein switch.

Authors:  Mudit Kakar; Amy B Cadwallader; James R Davis; Carol S Lim
Journal:  Pharm Res       Date:  2007-06-13       Impact factor: 4.200

7.  Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis.

Authors:  Tien-Phat V Huynh; Fan Liao; Caroline M Francis; Grace O Robinson; Javier Remolina Serrano; Hong Jiang; Joseph Roh; Mary Beth Finn; Patrick M Sullivan; Thomas J Esparza; Floy R Stewart; Thomas E Mahan; Jason D Ulrich; Tracy Cole; David M Holtzman
Journal:  Neuron       Date:  2017-12-06       Impact factor: 17.173

8.  Early pathogenesis of cardiac amyloid deposition in senile systemic amyloidosis: close relationship between amyloid deposits and the basement membranes of myocardial cells.

Authors:  Motoji Sawabe; Akihiko Hamamatsu; Tateki Ito; Tomio Arai; Kumiko Ishikawa; Kouji Chida; Naotaka Izumiyama; Naoko Honma; Kaiyo Takubo; Masamitsu Nakazato
Journal:  Virchows Arch       Date:  2003-02-26       Impact factor: 4.064

Review 9.  ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?

Authors:  Takahisa Kanekiyo; Huaxi Xu; Guojun Bu
Journal:  Neuron       Date:  2014-02-19       Impact factor: 17.173

10.  A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; James A Ripellino; Yongsheng Li; Stephen D Schmidt; Paul M Mathews; John D Fryer; David M Holtzman; Einar M Sigurdsson; Thomas Wisniewski
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.